Company Encyclopedia
View More
name
MaxCyte
MXCT.US
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.
755.08 B
MXCT.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking53/61
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-23.19%E
    • Profit Margin-132.58%E
    • Gross Margin76.63%A
  • Growth ScoreE
    • Revenue YoY-24.52%E
    • Net Profit YoY-27.69%D
    • Total Assets YoY-14.13%E
    • Net Assets YoY-15.48%E
  • Cash ScoreD
    • Cash Flow Margin-75.43%D
    • OCF YoY-24.52%E
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreA
    • Gearing Ratio15.55%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FY2025 EPS Estimates for MaxCyte Boosted by William Blair

    William Blair has increased its FY2025 EPS estimates for MaxCyte from ($0.46) to ($0.39) per share. The firm maintains a "Market Perform" rating on the stock. MaxCyte's recent earnings missed consensus estimates, reporting ($0.12) EPS against an expected ($0.11). The stock has a consensus rating of "Hold" with a target price of $7.00. Institutional investors have been actively trading MaxCyte shares, with significant inflows and outflows noted in the third quarter.

    Market Beat·
    US
    MXCT
    -1.32%
    Market Beat·
    US
    MXCT
    -1.32%

    MaxCyte | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 6.829 M

    LB filings·
    US
    MXCT
    -1.32%
    LB filings·
    US
    MXCT
    -1.32%

    MaxCyte Announces Q3 Results and Operational Restructuring

    MaxCyte reported Q3 results with a revenue of $6.8 million, down 16% year-over-year, while maintaining its 2025 revenue guidance. The company announced an operational restructuring aimed at cost reduction and profitability acceleration. MaxCyte added Moonlight Bio as a new SPL client, increasing total SPL agreements to 32. Analysts rate MXCT stock as a Buy with a $9.00 price target, though Spark's AI Analyst considers it Neutral due to financial challenges. MaxCyte focuses on cell-engineering technologies for next-generation therapies, with a market cap of $156.7 million.

    Tip Ranks·
    US
    MXCT
    -1.32%
    Tip Ranks·
    US
    MXCT
    -1.32%

    MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments

    MaxCyte reported a 16% year-over-year decline in Q3 revenue, primarily due to lower sales in instruments. Despite this, adjusted EBITDA exceeded analyst expectations, indicating effective cost management. The company has expanded its SPL program with a new agreement with Moonlight Bio, bringing total SPL agreements to 32. For 2025, MaxCyte anticipates core revenue to be flat to a 10% decline compared to 2024, with SPL-related revenue projected at $5 million. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $5.72, significantly above its recent closing price of $1.55.

    Reuters·
    US
    MXCT
    -1.32%
    Reuters·
    US
    MXCT
    -1.32%

    MaxCyte CFO Douglas Swirsky to Step Down in 2026

    MaxCyte Inc. announced that CFO Douglas Swirsky will step down in the first half of 2026. The company is currently searching for his successor, and Swirsky will remain in his role until a replacement is appointed, after which he will serve in an advisory capacity. MaxCyte expects no impact on operations or strategic priorities during this transition period.

    Reuters·
    US
    MXCT
    -1.32%
    Reuters·
    US
    MXCT
    -1.32%
    © 2025 Longbridge｜Disclaimer